Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function
/in Dendritic Cells, International PublicationsThe history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors
/in Brain Tumors in Children, Dendritic Cells, Glioblastoma, International PublicationsHepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape
/in Chronic Virus Hepatitis, International PublicationsEfficacy of superficial and deep regional hyperthermia combined with systemic chemotherapy and radiotherapy in metastatic melanoma
/in Hyperthermia, International Publications, Malignant MelanomaDendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients
/in Cervical Cancer, Dendritic Cells, International PublicationsIn vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells
/in Breast Cancer, Dendritic Cells, International PublicationsHyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent to co-culture with tumor lysate pulsed dendritic cells
/in Hepatocellular Carcinoma, International PublicationsHeat shock factor 1-independent activation of dendritic cells by heat shock: implication for the uncoupling of heat-mediated immunoregulation from the heat shock response
/in Hyperthermia, International PublicationsRecombinant Newcastle disease virus as a vaccine vector
/in International Publications, Newcastle Disease Virus
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer